Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MANUEL HIDALGO-MEDINA

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1467402164
CMS profile
945721
Location
NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$383,885.04

78 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Bristol Myers Squibb Company $383,769.85 73
ABBVIE INC. $63.22 3
Merck Sharp & Dohme LLC $31.03 1
TAIHO ONCOLOGY, INC. $20.94 1

Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MANUEL HIDALGO-MEDINA

NPI 1467402164 · CMS profile ID 945721

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1467402164?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MANUEL HIDALGO-MEDINA, NPI 1467402164, CMS profile ID 945721. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1467402164?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). MANUEL HIDALGO-MEDINA, NPI 1467402164, CMS profile ID 945721. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1467402164?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
MANUEL HIDALGO-MEDINA, NPI 1467402164, CMS profile ID 945721, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1467402164?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

78 matching records · $383,885.04 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 78 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–78 of 78.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Bristol Myers Squibb Company $176.7106/13/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1193055705 CMS
ABBVIE INC. $17.9805/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202043675 CMS
Bristol Myers Squibb Company $19.9905/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1193055623 CMS
Bristol Myers Squibb Company $31.3505/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1193055625 CMS
Bristol Myers Squibb Company $40.5005/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1193055629 CMS
Bristol Myers Squibb Company $673.2105/06/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1193055703 CMS
Bristol Myers Squibb Company $51.0005/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1193055621 CMS
Bristol Myers Squibb Company $66.0005/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1193055613 CMS
Bristol Myers Squibb Company $138.0005/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1193055617 CMS
Bristol Myers Squibb Company $25.1505/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1193055619 CMS
Bristol Myers Squibb Company $323.5905/04/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1193055699 CMS
Bristol Myers Squibb Company $598.0005/04/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1193055701 CMS
Bristol Myers Squibb Company $35,000.0003/21/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1193055681 CMS
Bristol Myers Squibb Company $1,052.2203/13/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1193055691 CMS
Bristol Myers Squibb Company $19.9902/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1193055611 CMS
Bristol Myers Squibb Company $5.5002/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1193055615 CMS
Bristol Myers Squibb Company $450.5702/12/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1193055697 CMS
Bristol Myers Squibb Company $46.1502/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1193055605 CMS
Bristol Myers Squibb Company $348.7502/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1193055607 CMS
Bristol Myers Squibb Company $69.7502/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1193055609 CMS
Bristol Myers Squibb Company $366.3402/11/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1193055693 CMS
Bristol Myers Squibb Company $349.0002/11/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1193055695 CMS
Bristol Myers Squibb Company $23.0002/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1193055723 CMS
Bristol Myers Squibb Company $77.0002/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1193055725 CMS
Bristol Myers Squibb Company $31.0002/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1193055727 CMS
Bristol Myers Squibb Company $210,000.0002/01/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1193055689 CMS
TAIHO ONCOLOGY, INC. $20.9401/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211407819 CMS
Merck Sharp & Dohme LLC $31.0301/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238287927 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,237.23 4
PY2021 $62,468.38 30
PY2022 $203,402.60 57
PY2023 $379,209.41 26
PY2024 $396,357.57 42
PY2025 $383,885.04 78

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $432,691.00 130
PY2024 Principal investigator $20,372.00 1
PY2022 Recipient $1,400.00 1
PY2020 Recipient $6,685.00 6
PY2020 Principal investigator $13,500.00 1
PY2019 Recipient $886.00 1
PY2019 Principal investigator $23,316.36 5

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

130 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $1,905.00 12/12/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618167
Principal investigator 1 Incyte Corporation $2,615.00 12/12/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618171
Principal investigator 1 Incyte Corporation $28,758.60 12/12/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618176
Principal investigator 1 Incyte Corporation $5,293.00 12/12/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618191
Principal investigator 1 Incyte Corporation $2,282.00 12/12/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618193
Principal investigator 1 Incyte Corporation $3,051.00 12/12/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618245
Principal investigator 1 Incyte Corporation $81.00 11/26/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618098
Principal investigator 1 Incyte Corporation $81.00 11/26/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618101
Principal investigator 1 Incyte Corporation $81.00 11/26/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618105
Principal investigator 1 Incyte Corporation $18.00 11/26/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618109
Principal investigator 1 Incyte Corporation $18.00 11/26/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618112
Principal investigator 1 Incyte Corporation $127.00 11/26/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618116
Principal investigator 1 Incyte Corporation $775.00 11/26/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618119
Principal investigator 1 Incyte Corporation $775.00 11/26/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618124
Principal investigator 1 Incyte Corporation $822.00 11/26/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618128
Principal investigator 1 Incyte Corporation $2,786.00 11/26/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618131
Principal investigator 1 Incyte Corporation $1,596.00 11/26/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618136
Principal investigator 1 Incyte Corporation $66.00 11/26/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618142
Principal investigator 1 Incyte Corporation $174.00 11/26/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618147
Principal investigator 1 Incyte Corporation $81.00 11/26/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618151
Principal investigator 1 Incyte Corporation $81.00 11/26/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618154
Principal investigator 1 Incyte Corporation $81.00 11/26/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618158
Principal investigator 1 Incyte Corporation $81.00 11/26/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618161
Principal investigator 1 Incyte Corporation $81.00 11/26/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618181
Principal investigator 1 Incyte Corporation $33.00 11/26/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618183
Principal investigator 1 Incyte Corporation $20.00 11/26/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618187
Principal investigator 1 Incyte Corporation $81.00 11/26/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618197
Principal investigator 1 Incyte Corporation $124.00 11/26/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618201
Principal investigator 1 Incyte Corporation $194.00 11/26/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618205
Principal investigator 1 Incyte Corporation $890.00 11/26/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618209
Principal investigator 1 Incyte Corporation $374.00 11/26/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618214
Principal investigator 1 Incyte Corporation $385.00 11/26/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618216
Principal investigator 1 Incyte Corporation $51.00 11/26/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618219
Principal investigator 1 Incyte Corporation $26.00 11/26/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618223
Principal investigator 1 Incyte Corporation $81.00 11/26/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618227
Principal investigator 1 Incyte Corporation $208.70 11/26/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618231
Principal investigator 1 Incyte Corporation $110.00 11/26/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618234
Principal investigator 1 Incyte Corporation $275.10 11/26/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618238
Principal investigator 1 Incyte Corporation $1,152.00 11/26/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618242
Principal investigator 1 Incyte Corporation $1,338.00 09/15/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617922
Principal investigator 1 Incyte Corporation $2,292.00 09/15/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617927
Principal investigator 1 Incyte Corporation $3,152.00 09/15/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617931
Principal investigator 1 Incyte Corporation $1,879.00 09/15/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617938
Principal investigator 1 Incyte Corporation $1,338.00 09/15/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617941
Principal investigator 1 Incyte Corporation $2,534.00 09/15/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617945
Principal investigator 1 Incyte Corporation $2,082.00 09/15/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617949
Principal investigator 1 Incyte Corporation $1,905.00 09/15/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617953
Principal investigator 1 Incyte Corporation $2,201.00 09/15/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617956
Principal investigator 1 Incyte Corporation $3,285.00 09/15/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618052
Principal investigator 1 Incyte Corporation $4,061.00 09/15/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618057
Principal investigator 1 Incyte Corporation $1,338.00 09/15/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618061
Principal investigator 1 Incyte Corporation $1,338.00 09/15/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618064
Principal investigator 1 Incyte Corporation $1,338.00 09/15/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618069
Principal investigator 1 Incyte Corporation $1,338.00 09/15/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618072
Principal investigator 1 Incyte Corporation $5,171.00 09/03/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617874
Principal investigator 1 Incyte Corporation $2,441.00 09/03/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617882
Principal investigator 1 Incyte Corporation $3,968.00 09/03/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617885
Principal investigator 1 Incyte Corporation $1,879.00 09/03/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617889
Principal investigator 1 Incyte Corporation $1,879.00 09/03/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617893
Principal investigator 1 Incyte Corporation $5,171.00 09/03/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617898
Principal investigator 1 Incyte Corporation $5,171.00 09/03/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617901
Principal investigator 1 Incyte Corporation $2,612.20 09/03/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617904
Principal investigator 1 Incyte Corporation $3,000.00 09/03/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617907
Principal investigator 1 Incyte Corporation $2,201.00 09/03/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617912
Principal investigator 1 Incyte Corporation $2,288.00 09/03/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617915
Principal investigator 1 Incyte Corporation $5,171.00 09/03/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617919
Principal investigator 1 Incyte Corporation $1,905.00 09/03/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618075
Principal investigator 1 Incyte Corporation $3,968.00 09/03/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618093
Principal investigator 1 Incyte Corporation $2,759.60 08/28/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617870
Principal investigator 1 Incyte Corporation $1,879.00 08/28/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617878
Principal investigator 1 Incyte Corporation $4,000.00 08/28/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618023
Principal investigator 1 Incyte Corporation $3,402.00 08/28/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618027
Principal investigator 1 Incyte Corporation $11,500.00 08/28/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618031
Principal investigator 1 Incyte Corporation $1,905.00 07/18/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617960
Principal investigator 1 Incyte Corporation $3,864.00 07/18/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617965
Principal investigator 1 Incyte Corporation $2,666.00 07/18/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617968
Principal investigator 1 Incyte Corporation $3,618.00 07/18/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617971
Principal investigator 1 Incyte Corporation $2,677.00 07/18/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617974
Principal investigator 1 Incyte Corporation $7,552.00 07/18/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617977
Principal investigator 1 Incyte Corporation $5,171.00 07/18/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617982
Principal investigator 1 Incyte Corporation $1,879.00 07/18/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617986
Principal investigator 1 Incyte Corporation $2,441.00 07/18/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617990
Principal investigator 1 Incyte Corporation $8,281.00 07/18/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617993
Principal investigator 1 Incyte Corporation $2,292.00 07/18/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617997
Principal investigator 1 Incyte Corporation $1,879.00 07/18/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618001
Principal investigator 1 Incyte Corporation $2,441.00 07/18/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618005
Principal investigator 1 Incyte Corporation $3,398.00 07/18/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618009
Principal investigator 1 Incyte Corporation $2,819.00 07/18/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618013
Principal investigator 1 Incyte Corporation $2,292.00 07/18/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618017
Principal investigator 1 Incyte Corporation $3,152.00 07/18/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618035
Principal investigator 1 Incyte Corporation $3,152.00 07/18/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618039
Principal investigator 1 Incyte Corporation $2,264.00 07/18/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618044
Principal investigator 1 Incyte Corporation $2,264.00 07/18/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618048
Principal investigator 1 Incyte Corporation $1,511.40 07/18/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618080
Principal investigator 1 Incyte Corporation $1,879.00 07/18/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618085
Principal investigator 1 Incyte Corporation $1,879.00 07/18/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240618090
Principal investigator 1 Incyte Corporation $7,552.00 06/13/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617826
Principal investigator 1 Incyte Corporation $7,815.00 06/13/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617830
Principal investigator 1 Incyte Corporation $5,171.00 06/13/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617833
Principal investigator 1 Incyte Corporation $2,292.00 06/13/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617837
Principal investigator 1 Incyte Corporation $3,152.00 06/13/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617841
Principal investigator 1 Incyte Corporation $7,815.00 06/13/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617844
Principal investigator 1 Incyte Corporation $1,879.00 06/13/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617847
Principal investigator 1 Incyte Corporation $2,441.00 06/13/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617851
Principal investigator 1 Incyte Corporation $601.10 06/13/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617854
Principal investigator 1 Incyte Corporation $2,411.00 06/13/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617859
Principal investigator 1 Incyte Corporation $7,815.00 05/19/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617809
Principal investigator 1 Incyte Corporation $2,441.00 05/19/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617813
Principal investigator 1 Incyte Corporation $5,171.00 05/19/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617818
Principal investigator 1 Incyte Corporation $2,201.00 05/19/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617821
Principal investigator 1 Incyte Corporation $1,879.00 05/19/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617824
Principal investigator 1 Incyte Corporation $4,329.00 05/19/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617863
Principal investigator 1 Incyte Corporation $5,171.00 05/19/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617867
Principal investigator 1 Novartis Pharmaceuticals Corporation $66,807.00 05/09/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICAL COLLEGE
Appendix F to the Precision Promise Master Protocol: Canakinumab and Spartalizumab in Combination with Nab-Paclitaxel and Gemcitabine in Subjects with Metastatic Pancreatic Cancer No dispute reported 06/30/2026 1190303837
Principal investigator 1 Incyte Corporation $627.30 03/17/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617770
Principal investigator 1 Incyte Corporation $4,963.00 03/17/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617774
Principal investigator 1 Incyte Corporation $1,879.00 03/17/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617777
Principal investigator 1 Incyte Corporation $5,226.00 03/17/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617781
Principal investigator 1 Incyte Corporation $2,292.00 03/17/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617785
Principal investigator 1 Incyte Corporation $2,564.00 03/17/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617797
Principal investigator 1 Incyte Corporation $5,171.00 03/17/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617804
Principal investigator 1 Incyte Corporation $1,750.00 01/17/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617746
Principal investigator 1 Incyte Corporation $4,000.00 01/17/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617749
Principal investigator 1 Incyte Corporation $5,000.00 01/17/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617754
Principal investigator 1 Incyte Corporation $15,000.00 01/17/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617758
Principal investigator 1 Incyte Corporation $2,000.00 01/17/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617761
Principal investigator 1 Incyte Corporation $11,500.00 01/17/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617766
Principal investigator 1 Incyte Corporation $2,500.00 01/17/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617789
Principal investigator 1 Incyte Corporation $1,500.00 01/17/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617793
Principal investigator 1 Incyte Corporation $1,000.00 01/17/2025 Non-covered Recipient Entity
WEILL CORNELL MEDICINE
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation No dispute reported 06/30/2026 1240617800